Holen Sie sich die Stockscreener-App
21.73
1.90%
-0.42
Handel nachbörslich:
21.85
0.12
+0.55%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$22.15
Offen:
$22.43
24-Stunden-Volumen:
2.14M
Relative Volume:
0.74
Marktkapitalisierung:
$2.28B
Einnahmen:
$2.20B
Nettoeinkommen (Verlust:
$-842.79M
KGV:
-2.5752
EPS:
-8.4382
Netto-Cashflow:
$-332.39M
1W Leistung:
-0.78%
1M Leistung:
+32.50%
6M Leistung:
-2.12%
1J Leistung:
-60.07%
1-Tages-Spanne:
$21.55
$22.49
1-Wochen-Bereich:
$20.83
$22.66
52-Wochen-Spanne:
$10.41
$64.80
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Firmenname
Sarepta Therapeutics Inc
Sektor
Branche
Telefon
617-274-4000
Adresse
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
21.73 | 2.33B | 2.20B | -842.79M | -332.39M | -8.4382 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2025-12-09 | Eingeleitet | Wedbush | Outperform |
| 2025-11-05 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-09-22 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-07-29 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-07-29 | Bestätigt | H.C. Wainwright | Sell |
| 2025-07-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-07-29 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-07-28 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-07-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-07-24 | Eingeleitet | Citigroup | Sell |
| 2025-07-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-07-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-21 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-07-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | Herabstufung | Mizuho | Outperform → Neutral |
| 2025-07-21 | Herabstufung | Needham | Hold → Underperform |
| 2025-07-21 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-18 | Herabstufung | Needham | Buy → Hold |
| 2025-06-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-06-17 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-06-16 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-16 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | Herabstufung | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-02 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-11-27 | Bestätigt | Needham | Buy |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Sell |
| 2024-11-07 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-07-29 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-12-13 | Fortgesetzt | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-21 | Eingeleitet | Wedbush | Outperform |
| 2023-10-31 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-04 | Eingeleitet | Citigroup | Buy |
| 2023-03-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Bestätigt | BTIG Research | Buy |
| 2022-12-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Bestätigt | Needham | Buy |
| 2021-12-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-08-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-01-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-11 | Herabstufung | UBS | Buy → Neutral |
| 2021-01-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Eingeleitet | Mizuho | Buy |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-08-21 | Bestätigt | Needham | Buy |
| 2019-07-09 | Bestätigt | Morgan Stanley | Overweight |
| 2019-07-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-10-12 | Eingeleitet | Bernstein | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Bestätigt | RBC Capital Mkts | Outperform |
| 2018-09-14 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-09-06 | Eingeleitet | Credit Suisse | Outperform |
| 2018-08-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Bestätigt | Robert W. Baird | Outperform |
| 2018-06-20 | Bestätigt | Needham | Buy |
| 2018-06-19 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Chipmakers Recap: Can Sarepta Therapeutics Inc deliver consistent EPS growth2026 Macro Moves & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Stock Report: Is Sarepta Therapeutics Inc vulnerable to short sellersRecession Risk & Fast Gain Stock Tips - baoquankhu1.vn
Why is Sarepta Therapeutics (SRPT) up 24.2% since last earnings report? - MSN
Sarepta drops as report suggests FDA needs new trials for Elevidys - MSN
Sarepta Therapeutics (SRPT) price target decreased by 16.58% to 25.25 - MSN
Sarepta plans FDA filings seeking full approval for two DMD therapies - MSN
Sarepta Therapeutics, Inc. (SRPT) stock price, news, quote and history - Yahoo Finance Singapore
Sarepta Therapeutics, Inc. (SRPT) Stock Forecasts - Yahoo Finance
Sarepta Therapeutics, Inc. (AB3A.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
SRPT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
A decade ago, these drugs tore apart the FDA. Today, they might be some patients' best hope - statnews.com
Antisense Oligonucleotides Market 2026-2033 | US$ 5,286.96 - openPR.com
Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & History - ca.finance.yahoo.com
Sarepta siRNA Data Adds New Pillar To Rare Disease Pipeline Narrative - Yahoo Finance
Is Sarepta Therapeutics (SRPT) Starting To Look Interesting Again After Recent Share Price Rebound - Sahm
TD Cowen Downgrades Sarepta Therapeutics (SRPT) Stock to Hold, Reduces PT - MSN
9 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
RBC Adjusts Price Target on Sarepta Therapeutics to $19 From $18, Maintains Sector Perform Rating - Moomoo
How The Sarepta Therapeutics (SRPT) Investment Story Is Shifting On Mixed Elevidys And Pipeline Views - Yahoo Finance
Trading the Move, Not the Narrative: (SRPT) Edition - Stock Traders Daily
Duchenne Muscular Dystrophy Therapeutics Market to Reach USD - openPR.com
Income Plays: What is the PEG ratio of Sarepta Therapeutics Inc2026 PreEarnings & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Sarepta Therapeutics (SRPT) Is Up 16.3% After Early siRNA Muscle Data Validates Avß6 Platform - Sahm
Aberdeen Group Boosts Stake in Sarepta Therapeutics - National Today
Aberdeen Group plc Increases Stake in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
The Precedent: Federal Circuit Upholds Gene Therapy Host Cell Claims Under 35 U.S.C. § 101 in Regenxbio Inc., Et Al. v. Sarepta Therapeutics, Inc., Et Al. - JD Supra
SG Americas Securities Trims Sarepta Therapeutics Stake - National Today
SG Americas Securities LLC Lowers Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta gets New Zealand approval for Huntington’s disease trial - Investing.com
Sarepta Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
SAREPTA THERAPEUTICS INC (1SRPT.MI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wealth Enhancement Advisory Services LLC Acquires 62,981 Shares of Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT) - The Globe and Mail
Sarepta Therapeutics, Inc. (SRPT) Stock forecasts - uk.finance.yahoo.com
SRPT Stock Price, Quote & Chart | SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) - ChartMill
Sarepta Therapeutics, Inc. (0L35.L) Stock Price, News, Quote & History - Yahoo! Finance Canada
Charcot-Marie-Tooth (CMT) Disease Market Size to Reach US$ - openPR.com
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Finanzdaten der Sarepta Therapeutics Inc-Aktie (SRPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):